Drugs / QL1706H
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06047431 | Oct 2023 → Dec 2024 | cancer | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QL1706H | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06047431 ↗ |
| Known as | QL1706 | “QL1706H is the subcutaneousely administered formulation of QL1706, it contains two unique monoclonal antibodies.” NCT06047431 ↗ |
| Modality | Monoclonal antibody | “contains two unique monoclonal antibodies” NCT06047431 ↗ |
| Route | Subcutaneous | “QL1706H is the subcutaneousely administered formulation” NCT06047431 ↗ |